Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2026-02-03 @ 12:37 AM
Study NCT ID:
NCT03097666
Status:
COMPLETED
Last Update Posted:
2022-04-22
First Post:
2017-03-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001471', 'term': 'Barrett Esophagus'}], 'ancestors': [{'id': 'D011230', 'term': 'Precancerous Conditions'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': "Patients with previously untreated (by means of ablation therapy) flat type Barrett's Esophagus (BE) (extent BE ≤C3) with Low-Grade Dysplasia (LGD) or High-Grade Dysplasia (HGD), or residual BE after removal of early adenocarcinoma"}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 24}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-03-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-04', 'completionDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-04-21', 'studyFirstSubmitDate': '2017-03-01', 'studyFirstSubmitQcDate': '2017-03-30', 'lastUpdatePostDateStruct': {'date': '2022-04-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-03-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose-related SAEs', 'timeFrame': '30 days', 'description': 'Safety will be evaluated by the incidence of Dose-related SAEs. Dose-related SAEs include pain in the treatment area, or any stricture (symptomatic or asymptomatic) preventing passage of the diagnostic endoscope at follow-up EGD.'}, {'measure': 'Efficacy: Percent Eradication by therapeutic dose', 'timeFrame': '8 weeks', 'description': 'Eradication percentage of BE confirmed by histological evidence of eradication of BE, after treatment with the therapeutic dose.'}], 'secondaryOutcomes': [{'measure': 'Incidence of AEs', 'timeFrame': 'up to 30 days post-treatment', 'description': 'Incidence of all serious and non-serious adverse events up to 30 days post-treatment.'}, {'measure': 'Post-procedure pain', 'timeFrame': '24 hours and 7 days post-procedure', 'description': 'Post-procedure pain in the area of the cryoablation treatment (scored on a 0 to 10 point VAS)'}, {'measure': 'Efficacy: Percent Regression', 'timeFrame': '8 weeks', 'description': 'Regression percentage at the first follow-up endoscopy, after 1 treatment with the therapeutic dose.'}, {'measure': 'Efficacy: Treatment', 'timeFrame': '8 weeks', 'description': 'Efficacy of treatment with CryoBalloon Swipe ablation system, defined as the proportion of patients with ≥80% regression of BE after 1 treatment.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Barrett Esophagus']}, 'referencesModule': {'references': [{'pmid': '38431103', 'type': 'DERIVED', 'citation': 'Sunakawa H, Yoda Y, Nonaka S, Suzuki H, Abe S, Ishiguro Y, Ikeno T, Wakabayashi M, Sato A, Nakajo K, Kadota T, Yano T. Prospective multicenter trial of the cryoballoon ablation system for superficial esophageal squamous cell carcinoma on post-endoscopic resection scars: a CRYO-SCAR study (EPOC1902). Gastrointest Endosc. 2024 Sep;100(3):429-437. doi: 10.1016/j.gie.2024.02.018. Epub 2024 Feb 29.'}]}, 'descriptionModule': {'briefSummary': 'The primary objective is to determine the safety and efficacy of the C2 CryoBalloon™ Swipe Ablation System ("CryoBalloon Swipe") used at increasing doses.', 'detailedDescription': "The procedure will be performed on an outpatient basis, and the CryoBalloon Swipe will be used for all ablations following the instructions for use provided with the product.\n\nPatients who meet the eligibility criteria will be assigned to one of the treatment groups and doses, depending on the order of their enrollment:\n\nIn phase I, the first 6 patients will be treated with Dose 1 (lowest).\n\nAll patients will have to undergo 8 week (±1 week) follow-up EGD to evaluate efficacy of the dose before the study continues.\n\nIf the follow-up endoscopies show that Dose 1 eradicates ≥80% of the treated BE (by median percentage) and no SAE's are reported, this dose is defined as the therapeutic dose and enrollment will proceed to phase II.\n\nIf Dose 1 eradicates \\<80% of the treated BE, enrollment in Phase I will continue at the next highest dose. Treatment doses will be escalated in this manner until the earlier of a dose-related Serious Adverse Event (SAE) or determination of the therapeutic dose based on endoscopic exam.\n\nWhen the therapeutic dose is determined, the study will proceed to Phase II to generate additional safety and efficacy data.\n\nPhase II\n\nPhase II will confirm the safety and efficacy of the therapeutic dose found in Phase I.\n\n\\---------------------------------------------------------------\n\nDose-related SAEs include pain in the treatment area greater than 6 (on VAS) on 24 hours and seven (7) days post-treatment; symptomatic stricture requiring an additional EGD with endoscopic dilation before the first follow-up EGD; symptomatic stricture at follow-up EGD; or any stricture (symptomatic or asymptomatic) preventing passage of the diagnostic endoscope at follow-up EGD. Any other serious adverse events within 30 days after treatment will also be evaluated by the Data and Safety Monitoring Board (DSMB) for relationship to the dose and severity.\n\nWhen a Dose-related serious adverse event occurs, the Holding Rule will be invoked and enrollment at that dose will be held until the DSMB has evaluated the event."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Patients with flat-type (Paris type 0-IIb) BE esophagus, with an indication for ablation therapy, meaning:\n\n * Diagnosis of LGD or HGD in BE (confirmed by baseline histopathological analysis), OR\n * Residual BE with any grade of dysplasia after endoscopic resection\n2. Prague Classification Score C≤3\n3. Patients should be ablative-naïve (no previous ablation therapy of the esophagus)\n4. Older than 18 years of age at time of consent\n5. Operable per institution's standards\n6. Provides written informed consent on the IRB-approved informed consent form\n7. Willing and able to comply with follow-up requirements\n\nExclusion Criteria:\n\n1. Esophageal stenosis or stricture preventing advancement of a therapeutic endoscope.\n2. Any endoscopically visualized lesion such as ulcers, masses or nodules.\n3. History of locally advanced (\\>T1a) esophageal cancer\n4. History of esophageal varices\n5. Prior distal esophagectomy\n6. Active esophagitis LA grade B or higher\n7. Severe medical comorbidities precluding endoscopy\n8. Uncontrolled coagulopathy\n9. Pregnant or planning to become pregnant during period of study\n10. Patient refuses or is unable to provide written informed consent\n11. Participation in another study with investigational drug within the 30 days preceding or during the present study\n12. General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation"}, 'identificationModule': {'nctId': 'NCT03097666', 'briefTitle': "Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus", 'organization': {'class': 'INDUSTRY', 'fullName': 'Pentax Medical'}, 'officialTitle': "Clinical Trial to Evaluate Safety and Dose Response Using the C2 CryoBalloon™ Swipe Ablation System for the Treatment of Barrett's Esophagus", 'orgStudyIdInfo': {'id': 'CP-0018'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': 'C2 Cryoballoon Swipe Ablation System', 'description': 'C2 Cryoballoon Swipe Ablation System', 'interventionNames': ['Device: C2 CRYOBALLOON SWIPE ABLATION SYSTEM']}], 'interventions': [{'name': 'C2 CRYOBALLOON SWIPE ABLATION SYSTEM', 'type': 'DEVICE', 'description': 'The C2 CryoBalloon Swipe Ablation System ("CryoBalloon Swipe") is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes.', 'armGroupLabels': ['C2 Cryoballoon Swipe Ablation System']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'AMC Medical Research B.V.', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'St. Antonius Hospital Nieuwegein', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Eindhoven', 'country': 'Netherlands', 'facility': 'Catharina Ziekenhuis te Eindhoven', 'geoPoint': {'lat': 51.44083, 'lon': 5.47778}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Data will not be shared.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pentax Medical', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}